Optimal Sample Size for Use in Neonatal Pharmacokinetic Studies

Bo‐Hao Tang1, Bu‐Fan Yao1, John van den Anker2, Wei Zhao3
1Department of Clinical Pharmacy, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China
2Division of Clinical Pharmacology, Children’s National Hospital, Washington, DC, USA
3Department of Clinical Pharmacy, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, China

Tóm tắt

Từ khóa


Tài liệu tham khảo

Wang J, Avant D, Green D, et al. A survey of neonatal pharmacokinetic and pharmacodynamic studies in pediatric drug development. Clin Pharmacol Ther. 2015;98(3):328–35.

Allegaert K, Smits A, van den Anker JN. Drug evaluation studies in neonates: how to overcome the current limitations. Expert Rev Clin Pharmacol. 2018;11(4):387–96.

Green DJ, Zineh I, Burckart GJ. Pediatric drug development: outlook for science-based innovation. Clin Pharmacol Ther. 2018;103(3):376–8.

Lim SY, Pettit RS. Pharmacokinetic considerations in pediatric pharmacotherapy. Am J Health Syst Pharm. 2019;76(19):1472–80.

Wang J, Kumar SS, Sherwin CM, et al. Renal clearance in newborns and infants: predictive performance of population-based modeling for drug development. Clin Pharmacol Ther. 2019;105(6):1462–70.

Illamola SM, Sherwin CM, van Hasselt JGC. Clinical pharmacokinetics of amikacin in pediatric patients: a comprehensive review of population pharmacokinetic analyses. Clin Pharmacokinet. 2018;57(10):1217–28.

Tod M, Jullien V, Pons G. Facilitation of drug evaluation in children by population methods and modelling. Clin Pharmacokinet. 2008;47(4):231–43.

Zhao Y, Yao BF, Kou C, et al. Developmental population pharmacokinetics and dosing optimization of cefepime in neonates and young infants. Front Pharmacol. 2020;11:14.

Kang D, Schwartz JB, Verotta D. A sample size computation method for non-linear mixed effects models with applications to pharmacokinetics models. Stat Med. 2004;23(16):2551–66.

Salem F, Ogungbenro K, Vajjah P, et al. Precision criteria to derive sample size when designing pediatric pharmacokinetic studies: which measure of variability should be used? J Clin Pharmacol. 2014;54(3):311–7.

Ogungbenro K, Aarons L. Sample-size calculations for multi-group comparison in population pharmacokinetic experiments. Pharm Stat. 2010;9(4):255–68.

Kang D, Schwartz JB, Verotta D. Sample size computations for PK/PD population models. J Pharmacokinet Pharmacodyn. 2005;32(5–6):685–701.

Mahmood I. Naive Pooled-data approach for pharmacokinetic studies in pediatrics with a very small sample size. Am J Ther. 2014;21(4):269–74.

Jacqz-Aigrain E, Leroux S, Thomson AH, et al. Population pharmacokinetic meta-analysis of individual data to design the first randomized efficacy trial of vancomycin in neonates and young infants. J Antimicrob Chemother. 2019;74(8):2128–38.

Wang YN, Jadhav PR, Lala M, et al. Clarification on precision criteria to derive sample size when designing pediatric pharmacokinetic studies. J Clin Pharmacol. 2012;52(10):1601–6.

Rob Tibshirani FL. bootstrap: functions for the book “An introduction to the bootstrap”. 2019. Available from: https://cran.r-project.org/web/packages/bootstrap/index.html.

Smith AM, Davis JM. Challenges and opportunities to enhance global drug development in neonates. Curr Opin Pediatr. 2017;29(2):149–52.

Matsuo Y, Matsumoto S, Wajima T, et al. Pharmacokinetic modeling and simulation for dose rationale of doripenem in neonates and infants. Drug Metab Pharmacokinet. 2020;35(1):145–50.

Zhao W, Le Guellec C, Benjamin DK Jr, et al. First dose in neonates: are juvenile mice, adults and in vitro-in silico data predictive of neonatal pharmacokinetics of fluconazole. Clin Pharmacokinet. 2014;53(11):1005–18.

Zhao W, Leroux S, Biran V, et al. Developmental pharmacogenetics of CYP2C19 in neonates and young infants: omeprazole as a probe drug. Br J Clin Pharmacol. 2018;84(5):997–1005.

Thomson AH, Whiting B. Bayesian parameter estimation and population pharmacokinetics. Clin Pharmacokinet. 1992;22(6):447–67.

Wu YE, Xu HY, Shi HY, et al. Carbapenem-resistant enterobacteriaceae bloodstream infection treated successfully with high-dose meropenem in a preterm neonate. Front Pharmacol. 2020;11:566060.